APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Central Nervous System (CNS) Stimulant Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Central Nervous System (CNS) Stimulant Drugs Market Analysis and Forecast 2026-2032

20 December 2025193 pages

Choose your research edition.

Industry ResearchCentral Nervous System (CNS) Stimulant Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Central Nervous System (CNS) Stimulant Drugs Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Central Nervous System (CNS) Stimulant Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Central Nervous System (CNS) Stimulant Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Central Nervous System (CNS) Stimulant Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Central Nervous System (CNS) Stimulant Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Central Nervous System (CNS) Stimulant Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Central Nervous System (CNS) Stimulant Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Central Nervous System (CNS) Stimulant Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Central Nervous System (CNS) Stimulant Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Central Nervous System (CNS) Stimulant Drugs include Takeda Pharmaceuticals, Sanofi, Thermo Fisher Scientific, Johnson and Johnson, Novartis, Merck, Roche, Eli Lilly and Company and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Central Nervous System (CNS) Stimulant Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Central Nervous System (CNS) Stimulant Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Central Nervous System (CNS) Stimulant Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Central Nervous System (CNS) Stimulant Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Central Nervous System (CNS) Stimulant Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Central Nervous System (CNS) Stimulant Drugs sales, projected growth trends, production technology, application and end-user industry.

Central Nervous System (CNS) Stimulant Drugs Segment by Company

Takeda Pharmaceuticals

Sanofi

Thermo Fisher Scientific

Johnson and Johnson

Novartis

Merck

Roche

Eli Lilly and Company

Pfizer

GlaxoSmithKline

Biogen

Shire

Perdue Pharma

Celltech

Astellas Pharma

Central Nervous System (CNS) Stimulant Drugs Segment by Type

Cocaine

Caffeine

Amphetamine

Others

Central Nervous System (CNS) Stimulant Drugs Segment by Application

Attention Deficit Hyperactivity Disorder (ADHD)

Narcolepsy

Others

Central Nervous System (CNS) Stimulant Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Central Nervous System (CNS) Stimulant Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Central Nervous System (CNS) Stimulant Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Central Nervous System (CNS) Stimulant Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Central Nervous System (CNS) Stimulant Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Central Nervous System (CNS) Stimulant Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Central Nervous System (CNS) Stimulant Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cocaine Major Manufacturers Table 3. Caffeine Major Manufacturers Table 4. Amphetamine Major Manufacturers Table 5. Others Major Manufacturers Table 6. Global Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Attention Deficit Hyperactivity Disorder (ADHD) Major Manufacturers Table 8. Narcolepsy Major Manufacturers Table 9. Others Major Manufacturers Table 10. Central Nervous System (CNS) Stimulant Drugs Industry Trends Table 11. Central Nervous System (CNS) Stimulant Drugs Industry Drivers Table 12. Central Nervous System (CNS) Stimulant Drugs Industry Opportunities and Challenges Table 13. Central Nervous System (CNS) Stimulant Drugs Industry Restraints Table 14. Global Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Region (2021-2026) Table 18. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Region (2027-2032) Table 19. Global Central Nervous System (CNS) Stimulant Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (tons) Table 20. Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2021-2026) & (tons) Table 21. Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2027-2032) & (tons) Table 22. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Region (2021-2026) Table 23. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Region (2027-2032) Table 24. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Central Nervous System (CNS) Stimulant Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Manufacturers (2021-2026) Table 28. Global Central Nervous System (CNS) Stimulant Drugs Sales Price (US$/ton) of Manufacturers (2021-2026) Table 29. Global Central Nervous System (CNS) Stimulant Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Central Nervous System (CNS) Stimulant Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Central Nervous System (CNS) Stimulant Drugs Manufacturers, Product Type & Application Table 32. Global Central Nervous System (CNS) Stimulant Drugs Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Central Nervous System (CNS) Stimulant Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Type (2021-2026) Table 39. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Type (2027-2032) Table 40. Global Central Nervous System (CNS) Stimulant Drugs Sales by Type 2021 VS 2025 VS 2032 (tons) Table 41. Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (tons) Table 42. Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2027-2032) & (tons) Table 43. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Type (2021-2026) Table 44. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Type (2027-2032) Table 45. Global Central Nervous System (CNS) Stimulant Drugs Price by Type (2021-2026) & (US$/ton) Table 46. Global Central Nervous System (CNS) Stimulant Drugs Price by Type (2027-2032) & (US$/ton) Table 47. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Application (2021-2026) Table 51. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Application (2027-2032) Table 52. Global Central Nervous System (CNS) Stimulant Drugs Sales by Application 2021 VS 2025 VS 2032 (tons) Table 53. Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (tons) Table 54. Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2027-2032) & (tons) Table 55. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Application (2021-2026) Table 56. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Application (2027-2032) Table 57. Global Central Nervous System (CNS) Stimulant Drugs Price by Application (2021-2026) & (US$/ton) Table 58. Global Central Nervous System (CNS) Stimulant Drugs Price by Application (2027-2032) & (US$/ton) Table 59. Takeda Pharmaceuticals Company Information Table 60. Takeda Pharmaceuticals Business Overview Table 61. Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 62. Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 63. Takeda Pharmaceuticals Recent Development Table 64. Sanofi Company Information Table 65. Sanofi Business Overview Table 66. Sanofi Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 67. Sanofi Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 68. Sanofi Recent Development Table 69. Thermo Fisher Scientific Company Information Table 70. Thermo Fisher Scientific Business Overview Table 71. Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 72. Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 73. Thermo Fisher Scientific Recent Development Table 74. Johnson and Johnson Company Information Table 75. Johnson and Johnson Business Overview Table 76. Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 77. Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 78. Johnson and Johnson Recent Development Table 79. Novartis Company Information Table 80. Novartis Business Overview Table 81. Novartis Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 82. Novartis Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 83. Novartis Recent Development Table 84. Merck Company Information Table 85. Merck Business Overview Table 86. Merck Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 87. Merck Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 88. Merck Recent Development Table 89. Roche Company Information Table 90. Roche Business Overview Table 91. Roche Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 92. Roche Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 93. Roche Recent Development Table 94. Eli Lilly and Company Company Information Table 95. Eli Lilly and Company Business Overview Table 96. Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 97. Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 98. Eli Lilly and Company Recent Development Table 99. Pfizer Company Information Table 100. Pfizer Business Overview Table 101. Pfizer Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 102. Pfizer Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 103. Pfizer Recent Development Table 104. GlaxoSmithKline Company Information Table 105. GlaxoSmithKline Business Overview Table 106. GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 107. GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 108. GlaxoSmithKline Recent Development Table 109. Biogen Company Information Table 110. Biogen Business Overview Table 111. Biogen Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 112. Biogen Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 113. Biogen Recent Development Table 114. Shire Company Information Table 115. Shire Business Overview Table 116. Shire Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 117. Shire Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 118. Shire Recent Development Table 119. Perdue Pharma Company Information Table 120. Perdue Pharma Business Overview Table 121. Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 122. Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 123. Perdue Pharma Recent Development Table 124. Celltech Company Information Table 125. Celltech Business Overview Table 126. Celltech Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 127. Celltech Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 128. Celltech Recent Development Table 129. Astellas Pharma Company Information Table 130. Astellas Pharma Business Overview Table 131. Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 132. Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio Table 133. Astellas Pharma Recent Development Table 134. North America Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021-2026) & (US$ Million) Table 135. North America Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2027-2032) & (US$ Million) Table 136. North America Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (tons) Table 137. North America Central Nervous System (CNS) Stimulant Drugs Sales by Type (2027-2032) & (tons) Table 138. North America Central Nervous System (CNS) Stimulant Drugs Sales Price by Type (2021-2026) & (US$/ton) Table 139. North America Central Nervous System (CNS) Stimulant Drugs Sales Price by Type (2027-2032) & (US$/ton) Table 140. North America Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021-2026) & (US$ Million) Table 141. North America Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2027-2032) & (US$ Million) Table 142. North America Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (tons) Table 143. North America Central Nervous System (CNS) Stimulant Drugs Sales by Application (2027-2032) & (tons) Table 144. North America Central Nervous System (CNS) Stimulant Drugs Sales Price by Application (2021-2026) & (US$/ton) Table 145. North America Central Nervous System (CNS) Stimulant Drugs Sales Price by Application (2027-2032) & (US$/ton) Table 146. North America Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. North America Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 148. North America Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 149. North America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 150. North America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026) & (tons) Table 151. North America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2027-2032) & (tons) Table 152. North America Central Nervous System (CNS) Stimulant Drugs Sales Price by Country (2021-2026) & (US$/ton) Table 153. North America Central Nervous System (CNS) Stimulant Drugs Sales Price by Country (2027-2032) & (US$/ton) Table 154. United States Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 155. Canada Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 156. Mexico Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 157. Europe Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021-2026) & (US$ Million) Table 158. Europe Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2027-2032) & (US$ Million) Table 159. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (tons) Table 160. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Type (2027-2032) & (tons) Table 161. Europe Central Nervous System (CNS) Stimulant Drugs Sales Price by Type (2021-2026) & (US$/ton) Table 162. Europe Central Nervous System (CNS) Stimulant Drugs Sales Price by Type (2027-2032) & (US$/ton) Table 163. Europe Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021-2026) & (US$ Million) Table 164. Europe Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2027-2032) & (US$ Million) Table 165. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (tons) Table 166. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Application (2027-2032) & (tons) Table 167. Europe Central Nervous System (CNS) Stimulant Drugs Sales Price by Application (2021-2026) & (US$/ton) Table 168. Europe Central Nervous System (CNS) Stimulant Drugs Sales Price by Application (2027-2032) & (US$/ton) Table 169. Europe Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 170. Europe Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 171. Europe Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 172. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 173. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026) & (tons) Table 174. Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country (2027-2032) & (tons) Table 175. Europe Central Nervous System (CNS) Stimulant Drugs Sales Price by Country (2021-2026) & (US$/ton) Table 176. Europe Central Nervous System (CNS) Stimulant Drugs Sales Price by Country (2027-2032) & (US$/ton) Table 177. Germany Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 178. France Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 179. U.K. Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 180. Italy Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 181. Russia Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 182. Spain Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 183. Netherlands Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 184. Switzerland Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 185. Sweden Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 186. Poland Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 187. China Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021-2026) & (US$ Million) Table 188. China Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2027-2032) & (US$ Million) Table 189. China Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (tons) Table 190. China Central Nervous System (CNS) Stimulant Drugs Sales by Type (2027-2032) & (tons) Table 191. China Central Nervous System (CNS) Stimulant Drugs Sales Price by Type (2021-2026) & (US$/ton) Table 192. China Central Nervous System (CNS) Stimulant Drugs Sales Price by Type (2027-2032) & (US$/ton) Table 193. China Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021-2026) & (US$ Million) Table 194. China Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2027-2032) & (US$ Million) Table 195. China Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (tons) Table 196. China Central Nervous System (CNS) Stimulant Drugs Sales by Application (2027-2032) & (tons) Table 197. China Central Nervous System (CNS) Stimulant Drugs Sales Price by Application (2021-2026) & (US$/ton) Table 198. China Central Nervous System (CNS) Stimulant Drugs Sales Price by Application (2027-2032) & (US$/ton) Table 199. Asia Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021-2026) & (US$ Million) Table 200. Asia Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2027-2032) & (US$ Million) Table 201. Asia Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (tons) Table 202. Asia Central Nervous System (CNS) Stimulant Drugs Sales by Type (2027-2032) & (tons) Table 203. Asia Central Nervous System (CNS) Stimulant Drugs Sales Price by Type (2021-2026) & (US$/ton) Table 204. Asia Central Nervous System (CNS) Stimulant Drugs Sales Price by Type (2027-2032) & (US$/ton) Table 205. Asia Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021-2026) & (US$ Million) Table 206. Asia Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2027-2032) & (US$ Million) Table 207. Asia Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (tons) Table 208. Asia Central Nervous System (CNS) Stimulant Drugs Sales by Application (2027-2032) & (tons) Table 209. Asia Central Nervous System (CNS) Stimulant Drugs Sales Price by Application (2021-2026) & (US$/ton) Table 210. Asia Central Nervous System (CNS) Stimulant Drugs Sales Price by Application (2027-2032) & (US$/ton) Table 211. Asia Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 212. Asia Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 213. Asia Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 214. Asia Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 215. Asia Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026) & (tons) Table 216. Asia Central Nervous System (CNS) Stimulant Drugs Sales by Country (2027-2032) & (tons) Table 217. Asia Central Nervous System (CNS) Stimulant Drugs Sales Price by Country (2021-2026) & (US$/ton) Table 218. Asia Central Nervous System (CNS) Stimulant Drugs Sales Price by Country (2027-2032) & (US$/ton) Table 219. Japan Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 220. South Korea Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 221. India Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 222. Australia Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 223. Taiwan Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 224. Southeast Asia Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 225. SAMEA Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021-2026) & (US$ Million) Table 226. SAMEA Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2027-2032) & (US$ Million) Table 227. SAMEA Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2026) & (tons) Table 228. SAMEA Central Nervous System (CNS) Stimulant Drugs Sales by Type (2027-2032) & (tons) Table 229. SAMEA Central Nervous System (CNS) Stimulant Drugs Sales Price by Type (2021-2026) & (US$/ton) Table 230. SAMEA Central Nervous System (CNS) Stimulant Drugs Sales Price by Type (2027-2032) & (US$/ton) Table 231. SAMEA Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021-2026) & (US$ Million) Table 232. SAMEA Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2027-2032) & (US$ Million) Table 233. SAMEA Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2026) & (tons) Table 234. SAMEA Central Nervous System (CNS) Stimulant Drugs Sales by Application (2027-2032) & (tons) Table 235. SAMEA Central Nervous System (CNS) Stimulant Drugs Sales Price by Application (2021-2026) & (US$/ton) Table 236. SAMEA Central Nervous System (CNS) Stimulant Drugs Sales Price by Application (2027-2032) & (US$/ton) Table 237. SAMEA Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 238. SAMEA Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 239. SAMEA Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 240. SAMEA Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 241. SAMEA Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021-2026) & (tons) Table 242. SAMEA Central Nervous System (CNS) Stimulant Drugs Sales by Country (2027-2032) & (tons) Table 243. SAMEA Central Nervous System (CNS) Stimulant Drugs Sales Price by Country (2021-2026) & (US$/ton) Table 244. SAMEA Central Nervous System (CNS) Stimulant Drugs Sales Price by Country (2027-2032) & (US$/ton) Table 245. Brazil Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 246. Argentina Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 247. Chile Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 248. Colombia Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 249. Peru Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 250. Saudi Arabia Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 251. Israel Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 252. UAE Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 253. Turkey Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 254. Iran Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 255. Egypt Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Table 256. Key Raw Materials Table 257. Raw Materials Key Suppliers Table 258. Central Nervous System (CNS) Stimulant Drugs Distributors List Table 259. Central Nervous System (CNS) Stimulant Drugs Customers List Table 260. Research Programs/Design for This Report Table 261. Authors List of This Report Table 262. Secondary Sources Table 263. Primary Sources List of Figures Figure 1. Central Nervous System (CNS) Stimulant Drugs Image Figure 2. Global Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Central Nervous System (CNS) Stimulant Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cocaine Image Figure 5. Caffeine Image Figure 6. Amphetamine Image Figure 7. Others Image Figure 8. Global Central Nervous System (CNS) Stimulant Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Central Nervous System (CNS) Stimulant Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. Attention Deficit Hyperactivity Disorder (ADHD) Image Figure 11. Narcolepsy Image Figure 12. Others Image Figure 13. Global Central Nervous System (CNS) Stimulant Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Central Nervous System (CNS) Stimulant Drugs Revenue (2021-2032) & (US$ Million) Figure 15. Global Central Nervous System (CNS) Stimulant Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Region (2021-2032) Figure 18. Global Central Nervous System (CNS) Stimulant Drugs Sales (2021-2032) & (tons) Figure 19. Global Central Nervous System (CNS) Stimulant Drugs Sales by Region: 2021 VS 2025 VS 2032 (tons) Figure 20. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Central Nervous System (CNS) Stimulant Drugs Sales YoY (2021-2032) & (tons) Figure 22. Europe Central Nervous System (CNS) Stimulant Drugs Sales YoY (2021-2032) & (tons) Figure 23. China Central Nervous System (CNS) Stimulant Drugs Sales YoY (2021-2032) & (tons) Figure 24. Asia (Excluding China) Central Nervous System (CNS) Stimulant Drugs Sales YoY (2021-2032) & (tons) Figure 25. South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales YoY (2021-2032) & (tons) Figure 26. Global Central Nervous System (CNS) Stimulant Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Central Nervous System (CNS) Stimulant Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Type (2021-2032) Figure 32. Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021 VS 2025 VS 2032) & (tons) Figure 33. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Type (2021-2032) Figure 35. Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Application (2021-2032) Figure 38. Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021 VS 2025 VS 2032) & (tons) Figure 39. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Application (2021-2032) Figure 41. North America Central Nervous System (CNS) Stimulant Drugs Revenue Share by Type (2021-2032) Figure 42. North America Central Nervous System (CNS) Stimulant Drugs Sales Share by Type (2021-2032) Figure 43. North America Central Nervous System (CNS) Stimulant Drugs Revenue Share by Application (2021-2032) Figure 44. North America Central Nervous System (CNS) Stimulant Drugs Sales Share by Application (2021-2032) Figure 45. North America Central Nervous System (CNS) Stimulant Drugs Revenue Share by Country (2021-2032) Figure 46. North America Central Nervous System (CNS) Stimulant Drugs Sales Share by Country (2021-2032) Figure 47. Europe Central Nervous System (CNS) Stimulant Drugs Revenue Share by Type (2021-2032) Figure 48. Europe Central Nervous System (CNS) Stimulant Drugs Sales Share by Type (2021-2032) Figure 49. Europe Central Nervous System (CNS) Stimulant Drugs Revenue Share by Application (2021-2032) Figure 50. Europe Central Nervous System (CNS) Stimulant Drugs Sales Share by Application (2021-2032) Figure 51. Europe Central Nervous System (CNS) Stimulant Drugs Revenue Share by Country (2021-2032) Figure 52. Europe Central Nervous System (CNS) Stimulant Drugs Sales Share by Country (2021-2032) Figure 53. China Central Nervous System (CNS) Stimulant Drugs Revenue Share by Type (2021-2032) Figure 54. China Central Nervous System (CNS) Stimulant Drugs Sales Share by Type (2021-2032) Figure 55. China Central Nervous System (CNS) Stimulant Drugs Revenue Share by Application (2021-2032) Figure 56. China Central Nervous System (CNS) Stimulant Drugs Sales Share by Application (2021-2032) Figure 57. Asia Central Nervous System (CNS) Stimulant Drugs Revenue Share by Type (2021-2032) Figure 58. Asia Central Nervous System (CNS) Stimulant Drugs Sales Share by Type (2021-2032) Figure 59. Asia Central Nervous System (CNS) Stimulant Drugs Revenue Share by Application (2021-2032) Figure 60. Asia Central Nervous System (CNS) Stimulant Drugs Sales Share by Application (2021-2032) Figure 61. Asia Central Nervous System (CNS) Stimulant Drugs Revenue Share by Country (2021-2032) Figure 62. Asia Central Nervous System (CNS) Stimulant Drugs Sales Share by Country (2021-2032) Figure 63. SAMEA Central Nervous System (CNS) Stimulant Drugs Revenue Share by Type (2021-2032) Figure 64. SAMEA Central Nervous System (CNS) Stimulant Drugs Sales Share by Type (2021-2032) Figure 65. SAMEA Central Nervous System (CNS) Stimulant Drugs Revenue Share by Application (2021-2032) Figure 66. SAMEA Central Nervous System (CNS) Stimulant Drugs Sales Share by Application (2021-2032) Figure 67. SAM

Scope & coverage.

Types
  • Cocaine
  • Caffeine
  • Amphetamine
  • Others
Applications
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Narcolepsy
  • Others
Companies covered
  • Takeda Pharmaceuticals
  • Sanofi
  • Thermo Fisher Scientific
  • Johnson and Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Shire
  • Perdue Pharma
  • Celltech
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Central Nervous System (CNS) Stimulant Drugs Market by Type
  3. 1.2.1 Global Central Nervous System (CNS) Stimulant Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cocaine
  5. 1.2.3 Caffeine
  6. 1.2.4 Amphetamine
  7. 1.2.5 Others
  8. 1.3 Central Nervous System (CNS) Stimulant Drugs Market by Application
  9. 1.3.1 Global Central Nervous System (CNS) Stimulant Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Attention Deficit Hyperactivity Disorder (ADHD)
  11. 1.3.3 Narcolepsy
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Central Nervous System (CNS) Stimulant Drugs Market Dynamics
  1. 2.1 Central Nervous System (CNS) Stimulant Drugs Industry Trends
  2. 2.2 Central Nervous System (CNS) Stimulant Drugs Industry Drivers
  3. 2.3 Central Nervous System (CNS) Stimulant Drugs Industry Opportunities and Challenges
  4. 2.4 Central Nervous System (CNS) Stimulant Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region
  3. 3.2.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region
  9. 3.4.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Manufacturers
  2. 4.1.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Central Nervous System (CNS) Stimulant Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Manufacturers
  6. 4.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Central Nervous System (CNS) Stimulant Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Central Nervous System (CNS) Stimulant Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Central Nervous System (CNS) Stimulant Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Central Nervous System (CNS) Stimulant Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Central Nervous System (CNS) Stimulant Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Central Nervous System (CNS) Stimulant Drugs Market CR5 and HHI
  16. 4.8.2 2025 Central Nervous System (CNS) Stimulant Drugs Tier 1, Tier 2, and Tier 3
5 Central Nervous System (CNS) Stimulant Drugs Market by Type
  1. 5.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type
  2. 5.1.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Type
  6. 5.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2032) & (tons)
  8. 5.2.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Central Nervous System (CNS) Stimulant Drugs Price by Type
6 Central Nervous System (CNS) Stimulant Drugs Market by Application
  1. 6.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application
  2. 6.1.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Application
  6. 6.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2032) & (tons)
  8. 6.2.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Central Nervous System (CNS) Stimulant Drugs Price by Application
7 Company Profiles
  1. 7.1 Takeda Pharmaceuticals
  2. 7.1.1 Takeda Pharmaceuticals Company Information
  3. 7.1.2 Takeda Pharmaceuticals Business Overview
  4. 7.1.3 Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  6. 7.1.5 Takeda Pharmaceuticals Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Central Nervous System (CNS) Stimulant Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Thermo Fisher Scientific
  14. 7.3.1 Thermo Fisher Scientific Company Information
  15. 7.3.2 Thermo Fisher Scientific Business Overview
  16. 7.3.3 Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  18. 7.3.5 Thermo Fisher Scientific Recent Developments
  19. 7.4 Johnson and Johnson
  20. 7.4.1 Johnson and Johnson Company Information
  21. 7.4.2 Johnson and Johnson Business Overview
  22. 7.4.3 Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  24. 7.4.5 Johnson and Johnson Recent Developments
  25. 7.5 Novartis
  26. 7.5.1 Novartis Company Information
  27. 7.5.2 Novartis Business Overview
  28. 7.5.3 Novartis Central Nervous System (CNS) Stimulant Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Novartis Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  30. 7.5.5 Novartis Recent Developments
  31. 7.6 Merck
  32. 7.6.1 Merck Company Information
  33. 7.6.2 Merck Business Overview
  34. 7.6.3 Merck Central Nervous System (CNS) Stimulant Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Merck Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  36. 7.6.5 Merck Recent Developments
  37. 7.7 Roche
  38. 7.7.1 Roche Company Information
  39. 7.7.2 Roche Business Overview
  40. 7.7.3 Roche Central Nervous System (CNS) Stimulant Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Roche Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  42. 7.7.5 Roche Recent Developments
  43. 7.8 Eli Lilly and Company
  44. 7.8.1 Eli Lilly and Company Company Information
  45. 7.8.2 Eli Lilly and Company Business Overview
  46. 7.8.3 Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  48. 7.8.5 Eli Lilly and Company Recent Developments
  49. 7.9 Pfizer
  50. 7.9.1 Pfizer Company Information
  51. 7.9.2 Pfizer Business Overview
  52. 7.9.3 Pfizer Central Nervous System (CNS) Stimulant Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  54. 7.9.5 Pfizer Recent Developments
  55. 7.10 GlaxoSmithKline
  56. 7.10.1 GlaxoSmithKline Company Information
  57. 7.10.2 GlaxoSmithKline Business Overview
  58. 7.10.3 GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  60. 7.10.5 GlaxoSmithKline Recent Developments
  61. 7.11 Biogen
  62. 7.11.1 Biogen Company Information
  63. 7.11.2 Biogen Business Overview
  64. 7.11.3 Biogen Central Nervous System (CNS) Stimulant Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Biogen Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  66. 7.11.5 Biogen Recent Developments
  67. 7.12 Shire
  68. 7.12.1 Shire Company Information
  69. 7.12.2 Shire Business Overview
  70. 7.12.3 Shire Central Nervous System (CNS) Stimulant Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Shire Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  72. 7.12.5 Shire Recent Developments
  73. 7.13 Perdue Pharma
  74. 7.13.1 Perdue Pharma Company Information
  75. 7.13.2 Perdue Pharma Business Overview
  76. 7.13.3 Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  78. 7.13.5 Perdue Pharma Recent Developments
  79. 7.14 Celltech
  80. 7.14.1 Celltech Company Information
  81. 7.14.2 Celltech Business Overview
  82. 7.14.3 Celltech Central Nervous System (CNS) Stimulant Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Celltech Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  84. 7.14.5 Celltech Recent Developments
  85. 7.15 Astellas Pharma
  86. 7.15.1 Astellas Pharma Company Information
  87. 7.15.2 Astellas Pharma Business Overview
  88. 7.15.3 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio
  90. 7.15.5 Astellas Pharma Recent Developments
8 North America
  1. 8.1 North America Central Nervous System (CNS) Stimulant Drugs Market Size by Type
  2. 8.1.1 North America Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Central Nervous System (CNS) Stimulant Drugs Price by Type (2021-2032)
  5. 8.2 North America Central Nervous System (CNS) Stimulant Drugs Market Size by Application
  6. 8.2.1 North America Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Central Nervous System (CNS) Stimulant Drugs Price by Application (2021-2032)
  9. 8.3 North America Central Nervous System (CNS) Stimulant Drugs Market Size by Country
  10. 8.3.1 North America Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Central Nervous System (CNS) Stimulant Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Central Nervous System (CNS) Stimulant Drugs Market Size by Type
  2. 9.1.1 Europe Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Central Nervous System (CNS) Stimulant Drugs Price by Type (2021-2032)
  5. 9.2 Europe Central Nervous System (CNS) Stimulant Drugs Market Size by Application
  6. 9.2.1 Europe Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Central Nervous System (CNS) Stimulant Drugs Price by Application (2021-2032)
  9. 9.3 Europe Central Nervous System (CNS) Stimulant Drugs Market Size by Country
  10. 9.3.1 Europe Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Central Nervous System (CNS) Stimulant Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Central Nervous System (CNS) Stimulant Drugs Market Size by Type
  2. 10.1.1 China Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Central Nervous System (CNS) Stimulant Drugs Price by Type (2021-2032)
  5. 10.2 China Central Nervous System (CNS) Stimulant Drugs Market Size by Application
  6. 10.2.1 China Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Central Nervous System (CNS) Stimulant Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Central Nervous System (CNS) Stimulant Drugs Market Size by Type
  2. 11.1.1 Asia Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Central Nervous System (CNS) Stimulant Drugs Price by Type (2021-2032)
  5. 11.2 Asia Central Nervous System (CNS) Stimulant Drugs Market Size by Application
  6. 11.2.1 Asia Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Central Nervous System (CNS) Stimulant Drugs Price by Application (2021-2032)
  9. 11.3 Asia Central Nervous System (CNS) Stimulant Drugs Market Size by Country
  10. 11.3.1 Asia Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Central Nervous System (CNS) Stimulant Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Central Nervous System (CNS) Stimulant Drugs Market Size by Type
  2. 12.1.1 SAMEA Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Central Nervous System (CNS) Stimulant Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Central Nervous System (CNS) Stimulant Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Central Nervous System (CNS) Stimulant Drugs Market Size by Application
  6. 12.2.1 SAMEA Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Central Nervous System (CNS) Stimulant Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Central Nervous System (CNS) Stimulant Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Central Nervous System (CNS) Stimulant Drugs Market Size by Country
  10. 12.3.1 SAMEA Central Nervous System (CNS) Stimulant Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Central Nervous System (CNS) Stimulant Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Central Nervous System (CNS) Stimulant Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Central Nervous System (CNS) Stimulant Drugs Value Chain Analysis
  2. 13.1.1 Central Nervous System (CNS) Stimulant Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Central Nervous System (CNS) Stimulant Drugs Production Mode & Process
  6. 13.2 Central Nervous System (CNS) Stimulant Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Central Nervous System (CNS) Stimulant Drugs Distributors
  9. 13.2.3 Central Nervous System (CNS) Stimulant Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst